⌘K

Login Start Free

Home/Filings/4/0000943819-25-000086

4//SEC Filing

Farrell Michael J. 4

Accession 0000943819-25-000086

CIK 0000943819other

View on SEC.gov Company Profile

Filed

Oct 8, 8:00 PM ET

Accepted

Oct 9, 11:03 AM ET

Size

9.3 KB

Accession

0000943819-25-000086

Insider Transaction Report

Form 4

Period: 2025-10-07

Farrell Michael J.

DirectorChairman and CEO

Transactions

Sale
ResMed Common Stock
2025-10-07$282.85/sh−8,009$2,265,332→ 467,792 total
Exercise/Conversion
ResMed Common Stock
2025-10-07$101.64/sh+8,009$814,035→ 475,801 total
Exercise/Conversion
ResMed Common Stock Options
2025-10-07−8,009→ 8,011 total
Exercise: $101.64From: 2019-11-11Exp: 2025-11-14→ ResMed Common Stock (8,009 underlying)

Holdings

ResMed Common Stock
(indirect: By Trust)
2,090

Footnotes (3)

[F1]The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
[F2]This transaction was executed in multiple trades at prices ranging from $280.95 - $283.90. The price reported above reflects the weighted average sale price.
[F3]Represents date options first become exercisable. Options vest 1/3 per year.

Documents

1 file

4
form4.xmlPrimary
PRIMARY DOCUMENT

Issuer

RESMED INC

CIK 0000943819

Entity typeother

Related Parties

1

filerCIK 0001485164

Filing Metadata

Form type: 4
Filed: Oct 8, 8:00 PM ET
Accepted: Oct 9, 11:03 AM ET
Size: 9.3 KB

View on SEC.gov